1. Presents
• Destination India • Challenges & Opportunities •
JW Marriott Hotel, Mumbai, India
20th -21st September 2006
Presentation via Video Conferencing
40 Leaders, in one place, at one time, for one reason,
The Ultimate Pharma Leadership experience
Why iis tthiis Summiitt Diifffferrentt ?
• Two-day event, specially designed for today's executives
whose time is more precious than ever.
• The only event for CEOs & Owners of Pharma and Biotech
Organizations on a single platform.
• Unmatched Speaker faculty and agenda.
• Extensive interaction & one-to-one sessions, exchange
views and networking with industry experts.
Focus Areas
The focus areas and session tracks at PHARMA LEADERSHIP SUMMIT will
revolve around the changing business paradigms ushered in by
globalization and liberalization over the last decade have prompted the
Indian Pharmaceutical companies to revisit their strategies for sustenance
& future growth. Within a focused and professional environment, the
Summit will seamlessly integrate one-to-one business meetings. Delegates
will meet with Solution Provider representatives via pre-scheduled and
tailored one-to-one business meetings.. The Summit builds on its
successful multi-track formula to network at all levels within the industry
and to meet 1:1 with industry leaders.
AIOCD
All India Organisation
of Chemists & Druggists
IDMA
SUPPORTING ASSOCIATION
Indian Drug Manufacturers Association
Pharmaceuticals Export Promotion Council
( Set By Ministry Of Commerce & Industry, Govt. Of India )
OPPI
Organization of pharmaceutical
producers of India
IPA
Indian pharmaceuticals Association
Dr. Daniel Vasella
Chairman & CEO
Novartis Ltd.
• Vision 2010 •
• Day One •
Mr. Hank McKinnell
Global Chairman & CEO
PFIZER
• Vision 2010 •
• Day Two •

2. 09.00 Registration & Welcome Coffee
09.30 Speakers Introduction
Conference Moderator & Anchor
Mr. S. Krishnakumar,
Head Corporate Business Development,
Alkem Labs Ltd.
09.45 Welcome Address
Chairman,
Mr. Ajit Singh,
ACG Worldwide,
10.15 Key Note Address (Via Video Conferencing)
Mr. Hank McKinnell,
Mr. Ranjit Shahani,
Dr. Ajit V. Dangi,
Mr. Ranga Iyer,
01.00 Networking Lunch
Global chairman,
Pfizer Ltd.
11.00 Tea/Cofee Break
11.30 Addressing The State Of The Pharmaceutical
Industry: Examining The Need For Effective
Leadership As The Industry Moves Further
into The Next Generation
Vice-Chairman & Managing Director,
Novartis Ltd.
12.00 Managing Intellectual Property in a
Knowledge Economy
Director General,
OPPI (Organisation of Pharmaceutical Producers Ltd.)
12.30 Impact of Mergers and acquisitions in post
IPR Regime
Managing Director,
Wyeth Ltd.
02.00 Advantage India ( Pharmaceuticals)
Its Challenges & Opportunities
Sustaining the position of 'Advantage India' is in
the hands of Indians and what Indians make of it
during its journey of shifting gear from Process to
Product patent regime in the global context.
Dr. Himadri Sen,
President Pharma Research and Regulatory Affairs
Lupin Ltd.
02.30 Consequences of Drug Discovery and
Developments on Pharma R&D
Dr. J. M. Khanna,
Executive Director & President - Life Sciences,
Jubilant Organosys Ltd.
03.00 Alternative Medicines & Holistic Therapies
- Past Present and Future
Managing Director,
Mr. Pulin Shroff,
Charak Pharma Ltd.
03.30 White Biotechnology - Way Ahead.
Managing Director,
Mr. C. L. Rathi,
Advanced Enzyme Technologies Ltd.
In west, Biotechnology is now divided in Green,
White, and Red. White Biotech is Industrial Biotech.
Let me focuss on that. The RED is Pharma
(Therepeutic Drugs, Vaccacins, etc), and Green is
Agri. Although at some point they do merge with
each other & there are applications in each
segment for another segment, currently they are
classified as above for broader Perspective.
04.00 Tea/Cofee Break
04.30 Pharma Out Sourcing & Contract
Manufacturing The Road Ahead.
Managing Director,
Mr. S. Mohan Krishna,
Sarvotham Care Ltd.
VP Marketing & Sales,
Mr. Prashant Mantravadi,
Sarvotham Remedies Ltd.
05.30 Innovation in India - Biotech strategy for
Human recourse skill development strategy
CMD,
Dr. Krishna M. Ella,
Bharat Biotech Ltd.
06.00 Formulation and Generic Market
Challenges ahead
CEO,
Mr. Rajiv Malik,
Matrix Labs Ltd.
06.30 PANEL DISCUSSION
DESTINATION INDIA- CHALLENGES &
OPPORTUNITIES OF INDIAN PHARMA INDUSTRY
Panel Members
•Mr. Ajit Singh, Chairman, ACG Worldwide.
•Mr. Ranjit Shahani,Vice-Chairman & MD, Novartis Ltd.
•Mr. Ranga Iyer, MD, Wyeth Ltd.
•Mr. Kewal Handa, Managing Director, Pfizer Ltd
•Dr. Swati Piramal, Director, Nicholas Piramal (I) Ltd.
•Dr. Himadri Sen, President Pharma Research and
Regulatory Affairs, Lupin Ltd.
•Mr. Samprada Singh, Chairman, Alkem Labs Ltd.
•Mr. Suresh Kare, CMD, Indoco Remedies Ltd.
•Mr. Dilip Coulagi, CMD, Sigma Labs Ltd.
•Mr. Vikram Aima, CMD, Ochoalabs Ltd.
•Mr. Tapan Ray, Management Consultant & Ex MD,
Abott India Ltd.
•Dr. Krishna M.Ella, CMD, Bharat Biotech Ltd.
•Mr. Rajiv Malik, CEO, Matrix Labs Ltd.
•Mr. D. B. Mody, Director, J B Chemicals &
Pharmaceuticals Ltd.
07.30 Closing Remarks Followed by Cocktail & Dinner

3. 09.00 Registration & Welcome Coffee
09.30 Speakers Introduction
Conference Moderator & Anchor
Mr. S. Krishnakumar,
Head Corporate Business Development,
Alkem Labs Ltd.
09.45 Key Note Address (Via Video Conferencing)
Dr. Daniel Vassela,
Mr. Habil F Khorakiwala,
Mr. Kewal Handa,
Mr. Sandeep Gupta,
Mr. Deepak Naik,
01.00 Networking Lunch
Global Chairman & CEO,
Novartis Ltd.
10.30 Key Note Address
CMD,
Wockhardt Ltd.
11.00 Tea/ Coffee Break
11.30 Pharma CEO's Yesterday, today and
Tomorrow
Managing Director,
Pfizer Ltd.
12.00 Successful Leadership through difficult times:
Achieving an historic turnaround through
focus, Execution & Personal Leadership.
Managing Director,
Eli Lilly Pharma India Ltd.
12.30 Uncovering The Optimal Sales Force Structure
Of The Future: Addressing The Need For A
Leaner, More Efficient Task Force.
Managing Director,
Eisai Pharmaceuticals Ltd.
02.00 Globalisation of Bio- pharmaceutical Industry
Challenges & Opportunities Ahead
Mr. Tapan Ray,
Management Consultant and Ex MD,
Abott India Ltd.
02.30 From Product Seller To Practice Partner:
Transforming The Image And The Reputation
The Pharmaceutical Industry
Mr. Narayan. B. Gad,
Chief Executive Formulations,
Panacea Biotec Ltd.
03.00 Opportunities and Challenges for Clinical
Research in India.
Dr. Chandrashekhar Potkar,
Executive Director Clinical Research,
Pfizer Ltd.
03.30 The Art of Averting a Brand Flop and Making
of a Blockbuster Molecule
Managing Director ,
Dr. Anuj Saxena,
Elder Healthcare Ltd.
04.00 Tea/Cofee Break
04.30 Biotechnology The way ahead,
CEO.Vice Chairman,
Mr. Vijay Moza,
ICRI, INDIA
05.00 Realizing tangible value and achieving
Business goals through partnership.
Sr. VP International,
Mr. S. M. Raina,
Alkem Labs Ltd.
Session Chairman
Director - International,
Mr. Alok Saxena,
Elder Pharmaceuticals Ltd.
05.30 Strategic Alliances & Collaboration in post
IPR Regime
Director,
Mr. Srinivas Lanka,
Aurobindo Pharma Ltd.
06.00 PANEL DISCUSSION
Panel Members
•Mr. Ajit Singh, Chairman, ACG Worldwide.
•Dr. Ajit .V. Dangi, Director General, OPPI
•Mr. Ranjit Shahani, Vice-Chairman & MD, Novartis Ltd.
•Mr. Ranga Iyer, Managing Director, Wyeth Ltd.
•Dr. Swati Piramal, Director, Nicholas Piramal (I) Ltd.
•Dr. Himadri Sen, President- Pharma Research and
Regulatory Affairs, Lupin Ltd.
•Mr. B.N.Singh, Chairman, Alkem Labs Ltd.
•Mr. Narayan Gad, CEO, Panacea Biotec Ltd.
•Mr. Deepak Naik, MD, Eisai Pharmaceuticals Ltd.
•Mr. Rajesh Jain, Joint MD, Panacea Biotec Ltd.
•Dr. Anuj Saxena, Director Marketing,
Elder Pharmaceuticals Ltd.
•Mr. Alok Saxena, Director International,
Elder Pharmaceuticals Ltd.
•Mr. Kewal Handa, Managing Director, Pfizer Ltd.
•Mr. Vikram Aima, CMD, Ochoalabs Ltd.
•Mr. Bhaskar Narayana, Director & CFO,
Natco Pharma Ltd.
•Mr. J. P. N. Singh, Director, Galpha Labs Ltd.
•Mr. Tapan Ray, Management Consultant and
Ex MD, Abott India Ltd.
•Mr. D. B. Mody, Director, J B Chemicals &
Pharmaceuticals Ltd.
07.00 Closing Remarks

4. Dr. Ajit Dangi heads the OPPI Secretariat
as its Director General. Organization of
Pharmaceutical Producers of India (OPPI)
is a premier association of research based
international and large Indian
pharmaceutical companies. Dr. Dangi is a
veteran in the Pharmaceutical Industry
and is former President & Executive
Director of Johnson & Johnson, India. He
was Vice President of OPPI from 1998 to
2000 and also served as Chairman of its
HRD Committee. He holds Masters and
Doctorate degrees in Pharmaceutical
Chemistry from University of London, U.K.
and has undergone an Advanced
Management Programme at the Kellogg
Graduate School of Business, Chicago,
U.S.A. He has over two and a half decades
of experience in Research, Manufacturing,
Sales & Marketing and General
Management in Pharmaceutical Industry
in India and abroad.
Mr. Ajit Singh, the Chairman of
Associated Capsules Group was
nominated Fellow of the American
Association of Indian Pharmaceutical
Scientists, being the first person
resident outside the United States to
be honored. He was also bestowed
with the DIWA Award - 2002,
instituted by Drug Inspector's Welfare
A s s o c i a t i o n ( Food & Drug
Administration, Mumbai), in
recognition of his enthusiastic,
valuable and resolute efforts to
develop the Pharmacy profession in
India. Associated Capsules Group is
one of the largest manufacturers of
hard gelatin capsules in the world and
is the most integrated partner to the
pharmaceutical industry, offering
solutions from formulation processing
to cartoning.
Mr. Samprada Singh, Chairman,
Alkem Labs Ltd
Alkem Laboratories Ltd. was started by
Mr. Samprada Singh (currently Chairman)
around three decades back in 1973 on the
very auspicious day of Dasshera. Today
Mr. Samprada Singh is one of the most
respected and successful entrepreneurs
of the Indian Pharmaceutical Industry.
The growth of Alkem and the success of
Mr. Samprada Singh is most amazing
since Mr. Samprada Singh started this
organization from scratch and through
tremendous dynamism, vision and
leadership has brought it to the top of the
Indian Pharmaceutical Industry today. To
Mr. Samprada Singh goes the major credit
of seeing Alkem through its various stages
of progress from the beginning, till today,
when Alkem is a name to reckon with in
the Indian Pharmaceutical Industry.
A Graduate in Arts from the University of
Mumbai, Mr. Alok Saxena, 38, holds a
number of memberships of professional
bodies from India and abroad such as the
Institute of Management (U.K.), the
Institute of Sales and Marketing
Management (U.K.), the Singapore
Institute of Management (Singapore), and
the United Kingdom Institute of Directors.
He is the son of Mr. Jagdish Saxena, the
Chairman and Managing Director, and has
been associated with the company from its
inception. He has wide and varied
experience and exposure and was working
in the Company as a Director of its
International Division.
Dr. Ajit V Dangi, Director General,
OPPI
Dr. Alok Saxena, Whole Time Director,
Elder Pharmaceuticals Ltd
Dr. Himadri Sen,
President Pharma Research & Regulatory Affairs,
Lupin Labs Ltd.
30 years in pharma research,
technology development / transfer,
plant support & regulatory affairs.
18 years in UK MNCs (Including 13
years in MNC and 11 years in BMS)
& 16 years in Indian Cos. (Ranbaxy
& Lupin) • Development & approval
of approx. 70+ INDs, NDAs &
ANDAs for US / EC. • 12 OCRS
developed & commercialised incl.
two product licencing to the US co's.
• More than 24 patents and 8
publications • Awarded “Research
Scientist” award by Pharma
Business & Technology in 2004 •
Awarded “Outstanding Performance
Award 2005-06” by IPER, Pune
(Institute of Pharmaceutical
Education & Research)
Mr. Ranga Iyer, Managing Director,
Wyeth Limited.
Mr. Ranga Iyer is the Managing
Director of Wyeth Limited. He joined
Wyeth in 1980 and rose to become its
Managing Director in the year 2000.
Before becoming Managing Director,
he has handled various responsibilities
in Finance and commercial functions.
He is the Director of Credence
Investment & Finance Limited in India
and of John Wyeth Brother in United
Kingdom. He was Chairman of the
Pricing & Taxation Committee of OPPI.
As Chairman of this key committee, he
actively liaised with the Government
on behalf of OPPI on pricing and
taxation issues that impact the
pharma industry. He has now taken
over as Chairman of OPPI Marketing
Committee. Mr. Iyer holds a Post
Graduate degree in Commerce and
MBA in Finance from Bombay
University.
Mr. Ajit Singh, Chairman,
ACG -Worldwide

5. Dr. Ajit V Dangi, Director General, OPPI
“As the Indian economy begins to globalize, and the Pharmaceutical Industry enters the IPR Regime, We are at a major
inflexion point in the history of this industry. If we manage this paradigm shift effectively, where innovation is going to be the
key strategic driver for success, We will emerge as a global powerhouse”.
Mr. Tapan Ray, Management Consultant, Ex MD, Abott India Ltd
I very much support and appreciate your admirable initiative to bring the key thinkers, leaders and decision makers of the
Healthcare Industry under one high level platform to help them present, discuss and debate the key issues and opportunities
of the Industry in the rapidly evolving global scenario. This, I reckon, will not only be an intellectual and quite a cerebral feast
for the participants but more importantly is expected to provide enough food for thought to help chart a tangible and time-bound
road map in the respective areas of business focus of the individual companies.
Mr. J. M. Khanna, Executive Director & President - Life Sciences, Jubilant Organosys Ltd.,
The timing of “Pharma Leadership Summit” could not have been more opportune given the paradigm shifts that the industry is
witnessing globally. For Indian Pharma, these changes are exciting as it promises exponential growth in generics and would
strengthen the Pharma to service International Pharma and Biotech companies e.g. contract manufacturing, clinical research,
complex multi disciplines of drug discovery etc. I hope the deliberations at the summit would improve our understanding for
International business and research. I wish the summit a grand success!
Mr. Dilip S. Coulagi, Chairman & Managing Director, Sigma Labs Ltd
The pharma industry, or rather the entire healthcare fraternity in India stands on the threshold of great potential growth, since
we have the manpower to get the world's jobs done effectively and successfully at minimum cost, and we are farther along the
learning curve than most emerging countries. The deterrents/hindrances are all of government origin: poor and expensive
infrastructure, onerous and burdensome overregulation in almost all fields but particularly in the pharma field and the all
pervasive culture of delay and corruption. A major irritant to me personally is our tribe of hypocritical politicians and babus
mouthing pious platitudes without ever having any sincere desire to ease the way for the entrepreneurs of the country, or even
to the best for the people of the country, especially the poor.
Mr. C. L. Rathi, Managing Director, Advanced Enzyme Technologies Ltd.
The Pharmaceutical industry & Biotechnology industry are at a cross road of new opportunities based on business creation &
Innovation. Indian Entrepreneurship is world class. Many NRI's have shown their abilities abroad & several have shown it in
India too.
Now it is a time to create new history & create "Made In India" Brand like today many Japanese Companies have shown the
world for Japanese Companies & products.
We must all seat together & work out a plan to make it happen. This summit can be a good opportunity in that direction. I am
very happy to see the various topics of discussions there.
Mr. S. M. Raina, Sr. Vice President International Operations, Alkem Labs Ltd.
The idea of holding this Summit is at the most opportune time. India is becoming a hub for Global Pharma Industry which is
throwing plethora of opportunities to the Indian Pharma Companies. While these positive developments are welcome, there
are also numerous questions and doubts which arise while availing these opportunities which need to be thrashed in forums
such as this where Industry leaders would assemble and share their thoughts. I congratulate Informedia India Pvt Ltd for
organising this event and wish them a great success in organising this event.
Mr. J. P. N. SINGH, Director, Galpha Labs Ltd.
“Presently Patent has Not Affected Indian market considerably as seen abroad & will not affect because patent drug cannot
replace the current prescription pattern. i.e. the Purchase power of Indian population doesnot match patented drug price
structure.In Abroad, the patented drugs have the support of insurance companies reimbursement policy. In India, we are just
starting to have the medical expenses reimbursement by Companies like Mediclaim.Indian Pharma Companies would continue
to introduce new products which are patent expired & also try to consolidate their base quickly. The Indian Pharma Industries
anticipated growth is greater than 10% because of Government open policy. Nowadays, people are more conscious on health
management & lifestyle drugs have come into focus. Special segments including Gediatric practice is gaining momentum.
People will be more conscious on spending for medicine & health e. g. prophylactic like vaccines would get increased use.”
Mr. K.HARI RAM, Country Manager, Galderma India Pvt. Ltd.
“ India is on the move. Interesting transformation is taking place in the country. As such, the Indian pharmaceutical industry is
rated high among the developing countries for quality, technology and wide range of products.
It is therefore, an opportune moment and a commendable initiative for organizing The Pharmaceutical Leadership summit
and thus bringing together the industry leaders and thinkers under roof. I am sure this forum will provide an opportunity to
showcase the strength and the future hidden potential of the Indian Pharmaceutical industry, more so, in the context of the
current wave of globalization. I am sure this summit will help in providing a clear road map and direction to capitalize on the
favorable conditions that will put the Indian pharmaceutical industry on par with the top global players. I wish this summit all
success. “

6. Tabletop Display
YAMUNA GANGA SARASWATI
MAIN ENTRANCE
Stall Details
Receivables of Exhibitors
• Display Table • Chairs • Spot Lights
• Dustbin • Carpet (Synthetic)
• Company Name on Booth
What You Get ?
• Name & Logo in Entire Event Promotional
Campaigns
• 2 Minute Display of your Presentation in
Refreshment /Lunch/Dinner Breaks
• One to One Meeting with the Delegates
• Listing in the event catalog to be
distributed at the summit as well as to
5,000 Companies
Stall Size 2x3 meter(6sq.m)
No. Of Stalls 12
Contact
For Stall Booking & Sponsorship
• V.V. Ashok
• Tel: + 91 22 28506308 - 12
• Fax: + 91 22 28509590
• Email : vvashok@informedia-india.com
Promotional Opportunities at Managing Construction Risks Conferences
The Conference will attract senior decision makers from across the construction industry Sponsorship
Opportunities are available. Take advantage of this exclusive gathering to crate corporate exposure and
publicity for your company. Our sponsorship packages can be tailor made to your promotional needs and
budgets.

7. Why Should you book a VIP About the Conference Delegate Package?
Stand out from the crowd! Bring a group of 5 or more of
your staff or clients and take one of our exclusive VIP
packages. You will receive the following benefits :
• A Chance to meet our Speakers at an exclusive event !
• A Rare opportunity to meet with the Industry Veterans
• One-to-one meeting with the person whom you would
like to interact (for more information please get in touch
with the undersigned)
VIP packages are available for groups of 5 or more and
numbers are strictly limited. For more information,
Contact :
• Pushpalata Ramteke
on + 91 22 2850 6307-12
or email : marketing@informedia-india.com
The pharmaceutical and life sciences industry is undergoing a
period of profound transformation. Many analysts agree that
the industry is moving from the era of the “blockbuster drug” to
a new operating model known as personalized medicine. While
achieving success in research and development continues to
define those who will be the industry's winners and losers, other
issues are increasingly demanding the attention of top
management. They include navigating the challenges of global
regulatory compliance, optimizing the supply chain, achieving
marketing excellence and effectively managing organizational
complexity on a global scale. These issues along with increased
scrutiny of the industry's business practices and difficult
questions over the safety of marketed drugs have created
substantial tensions between the industry and its stakeholders.
The Summit will deliberate critical leadership topics
confronted by the Industry in general & the CEO’s in particulars.
Wishing you a pleasant business interaction at the summit.
Delegate Breakdown
CEOs & MDs - 50%
Heads of Sales/Marketing - 12%
Heads of R&D, QC, QA - 10%
Heads of Production - 10%
Heads of Logistics, Supply Chain, Consultants - 08%
Hotel information
Official Travel Agent
For Travel Assistance please contact
Komal Ahuja & Neeta Ahuja
Nav Bhavna, G.No 5, V.S. Marg,
Prabhadevi, Mumbai - 400025
• Tel :56043922/3 • Fax :24226990
• Cell : 919820338506 / 919820825048
Hotel JW Marriott,
Juhu Tara Road, Mumbai, 400 049, India
• Tel : +91 22 66933 000 • Fax : 6693 3100

8. Please tick
PHARMACEUTICAL LEADERSHIP SUMMIT, 20th & 21st September 2006, Mumbai
I enclose my Cheque/Draft payable to INFORMEDIA INDIA PVT. LTD.
I am paying by bank transfer (copy attached)
I cannot attend this event but
I would like to purchase the Conference Documentation
@ EURO 210 / INR 11,000+ 12.24 % Service Tax per set
91SM001S Please put me on your mailing list
1st
D
E
L
E
G
A
T
E
REGISTRATION FORM
Yes! I / we will attend the conference,
Signature
2nd
D
E
L
E
G
A
T
E
3rd
D
E
L
E
G
A
T
E
Name: Dr/Mr/Ms (1st Name) :
(middle Name):
(last Name) :
E-mail :
Job Title :
Department :
Name: Dr/Mr/Ms (1st Name)
(middle Name)
(last Name)
E-mail :
Job Title :
Department :
Name: Dr/Mr/Ms (1st Name)
(middle Name)
(last Name)
E-mail :
Job Title :
Department :
Company Name :
Nature of Business :
Address :
Tel./ Mobile :
Fax :
Name & Designation of Approving Authority :
HOTEL INFORMATION
Hotel JW Marriot, Juhu Tara
Road, Mumbai, 400 049, India
• Tel : +91 22 66933 000
• Fax : 6693 3100
REGISTRATION & PAYMENT
Payment by INR bank draft or
cheque should be made in Favour
of “Informedia India Pvt. Ltd.”
to be sent to
Informedia India Pvt. Ltd.
204 - 205, Town Centre,
Andheri-Kurla Road, Sakinaka,
Andheri (E), Mumbai - 400059.
Tel: (91) (22) 28506308 - 12
Fax: (91) (22) 28509590
EMAIL AT
marketing@informedia-india.com
PAYMENT BY TELEGRAPHIC
transfer in INR must be made to
“Informedia India Pvt. Ltd.”
A/C No: 499-011989-001
Hongkong and Shanghai Banking
Corporation Limited,
K 14-18, Sector 18,
Noida-201301, U.P, India
FOR GROUP DISCOUNTS
please contact our sales staff.
IMPORTANT NOTE
Please quote the name of the
delegate and event title on the
advice when remitting payment.
Bank charges are to be deducted
from participating organisation’s
own accounts. Attendance will only
be permitted upon reciept of full
payment.
It may be necessary for reasons
beyond the control of the organiser
to alter the content and the event
date or location or the identity of the
speaker.
Fee is net and exclusive of all taxes. Fee includes Luncheons, refreshments and
complete set of documentation.
It does not include the cost of accommodation and travel.
Cancellations & Substitutions
Cancellations received in writing before 01st August 06 will be refunded
less EURO 210/ INR 11,000 administration fee. Thereafter, cancellations
are not refundable. Participants may be substituted at any time.
Delegate Fees
+ 12.24 %
Service Tax
Nos. Of Delegates EURO INR
Single Delegate 510 29,500
Two Delegates 467 27,000
Three Delegates 432 25,000
Five Delegates & More 346 20,000
International Delegates 800 46,300
• REGISTER NOW! FAX BACK TO: +91(22) 28509590